IAH'S BiG DROP

Major Houston airport lands on list of hardest hit during the pandemic

Bush Intercontinental has seen a massive drop in travelers since the pandemic. Photo courtesy of Houston Airport System

Since the World Health Organization announced the COVID-19 as a global pandemic on March 11, few industries have slowed as dramatically as air travel. Airlines made massive cuts in services and jockeyed for government assistance. Some, such as United, announced furloughs of up to 45 percent of its U.S. based workers, some 36,000 employees.

Local airports such as George Bush Intercontinental witnessed a staggering drop in travelers.

Just how bad is the hit? Finance website FinanceBuzz crunched the numbers from the U.S. Bureau of Transportation to determine the pandemic's effect on the 30 busiest airports in the nation. The site examined the number of departing passengers on domestic flights from June 2019 and compared them to June of this year.

Houston's Bush Intercontinental (IAH) saw a dramatic decrease in traffic of 82.83 percent, according to FinanceBuzz. June 2019 saw 1,473,575 departing passengers, compared to just 253,036 in June of this year. That drop puts IAH at No. 13 in the top 15 airports with the biggest traffic drops in the U.S.

For some perspective, the airport with the biggest plunge is New York City's LaGuardia, which saw 1,281,848 travelers depart in June 2019, while a paltry 133,272 departed this June, for a 89.60 percent drop.

But it's not all gloom and doom for Texas airports. FinanceBuzz also looked at airports making the best recovery from April to June of this year. Overall, Dallas-Fort Worth International Airport saw the biggest increase in departing passengers, with 190,038 flying out in April 2020 and a whopping 998,875 flying out in June, for a jump of 425.62 percent.

The airport with the fastest recovery? That title goes to Chicago Midway International Airport, which saw 30,693 departures in April and 338,884 in June, for a leap of 1004.11 percent.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News